Skip to search formSkip to main contentSkip to account menu

LDK378

Known as: LDK 378 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
The chimeric protein echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase, resulting from the… 
2017
2017
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that is often overexpressed in rhabdomyosarcoma (RMS). However… 
2016
2016
We report on the case of a patient affected by advanced non-small cell lung cancer (NSCLC) harboring an anaplastic lymphoma… 
2015
2015
106 Background: Here we describe 8 ongoing single agent clinical protocols under Novartis’ “Signature” program involving… 
2014
2014
BACKGROUND: Ceritinib is an ALK inhibitor (ALKi) recently approved for patients with ALK+ advanced NSCLC. Efficacy and safety… 
2012
2012
3007 Background: LDK378 is a novel, potent and selective small molecule anaplastic lymphoma kinase (ALK) inhibitor (IC50 0.00015… 
2012
2012
Upon reinstitution of the Lithuanian state in the beginning of the twentieth century, some people reflected back to the times… 
2011
2011
Kursus Tamadun Islam dan Tamadun Asia (TITAS) merupakan kursus generik yang perlu diambil oleh semua pelajar di universiti tanpa…